The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma

European Journal of Cancer Care
O SencanF Icli

Abstract

There are few reports on use of symptomatic benefits as an alternative or adjunctive for the assessment of objective response in chemotherapy of the advanced cancer. This study is performed to assess the symptomatic benefits (the clinical benefit response), in addition to the efficacy and toxicity of cisplatin plus infusional 5-fluorouracil (5-FU) combination as second-line therapy in patients with advanced gastric cancer. Fifty-eight advanced gastric cancer patients with previous chemotherapy were enrolled into the study. Cisplatin 20 mg/m(2) was given for 5 days, and 5-FU was given 1000 mg/m(2) as 20 h continuous infusion for 5 days, repeated every 28 days. The overall objective response rate was 11.3%, and overall tumour control rate was 33.9%. The clinical benefit response, in terms of weight gain, reduction in analgesic consumption and the improvement in performance status observed in 12 patients [six patients with partial response (PR) and six patients with stable disease (SD)] (22.6%), while the rates of the clinical benefit response in patients with PR and with SD were 100% and 50% respectively. Cisplatin plus infusional 5-FU combination seems to improve disease-related symptoms (clinical benefit response) of patients w...Continue Reading

References

Jan 1, 1992·Hematological Oncology·J S Macdonald
May 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D MachoverJ B Fourtillan
Jun 1, 1983·European Journal of Cancer & Clinical Oncology·M BeerF Cavalli
Feb 1, 1996·Anti-cancer Drugs·D L Schipper, D J Wagener
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A WebbM Meehan
Feb 1, 1997·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B GlimeliusR Heuman
Jan 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·H Burris, A M Storniolo
Jun 23, 1998·Anti-cancer Drugs·S CascinuG Catalano
Dec 6, 2000·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F GrazianoS Cascinu
Feb 15, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T YamaoY Shimada
Feb 25, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D Y KimN K Kim
Dec 18, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L AssersohnA R Norman
Mar 17, 2004·Japanese Journal of Clinical Oncology·Jong Ho ChunJae-Moon Bae

❮ Previous
Next ❯

Citations

Apr 7, 2010·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Young Saing KimDong Bok Shin
Aug 21, 2009·Journal of Pain and Symptom Management·Gülcan BağçivanAhmet Ozet
Nov 12, 2015·World Journal of Gastroenterology : WJG·Dheepak KanagavelSergei Tjulandin

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.